Johnson & Johnson Shares Jump 4.0% After Tecvayli Multiple Myeloma Approval Nod

JNJ•2026-06-29

Johnson & Johnson secured a positive CHMP opinion for its Tecvayli and Darzalex SC combination to treat relapsed/refractory multiple myeloma after one prior therapy. The stock climbed 4.0% on volume above its 30-day average, fueled by recent upward revisions to its earnings estimates that may portend further gains.

1. Regulatory Milestone for Tecvayli

On June 29, 2026, J&J received a favorable CHMP opinion recommending Tecvayli in combination with Darzalex SC for patients with relapsed or refractory multiple myeloma after one prior therapy. This expands the therapy's potential EU market and sets the stage for final European Commission review in the coming months.

2. Share Surge Driven by Earnings Revisions

Following the CHMP news, the stock jumped 4.0% on volume above its 30-day average as analysts raised their 2026 earnings projections. Upward estimate revisions point to a potential continuation of the rally, with investors eyeing J&J’s broader pipeline catalysts and financial outlook.